publication venue for
- Adaptive Steroid Tapering Impedes Corticosteroid-free Remissions Compared with Forced Tapering in Clinical Trials of Ulcerative Colitis 2024
- OP05 Association of ultra-processed food intake with risk of Inflammatory Bowel Disease from the prospective urban rural epidemiology (PURE) study: A prospective cohort study 2021
- A randomised, placebo-controlled pilot trial of faecal microbiota transplantation for paediatric Crohn's disease 2020
- Effectiveness and safety of ustekinumab in patients with Crohn's disease: a real-world experience 2020
- Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study 2020
- Feasibility of the first paediatric randomised controlled pilot trial of faecal microbiota transplant for ulcerative colitis 2020
- Ileal ulcer size significantly impacts the ability to achieve endoscopic remission: a post-hoc analysis from the SONIC trial 2020
- Perceptions of faecal microbiota transplantation in patients with ulcerative colitis 2020
- Qualitative perspectives of parent and child participants from a trial of faecal microbiota transplant for paediatric ulcerative colitis 2020
- Results of the first paediatric randomised controlled trial of faecal microbiota transplant for ulcerative colitis 2020
- Mode of delivery and risk of inflammatory bowel disease 2019
- Surveillance colonoscopies in ulcerative colitis: does it make a difference? 2019
- P071 Supporting extrapolation of indications for ABP 501, the first adalimumab biosimilar: focus on Crohn’s disease 2019
- P607 Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease 2019
- P847 Perceptions of faecal microbiota transplantation in a paediatric ulcerative colitis population (PediFETCh Trial) 2019
- Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open 2018
- Higher adalimumab maintenance regimens are more effective than standard maintenance doses in Crohn's disease patients who have failed infliximab 2018
- Incidence of venous thromboembolic complications in controlled trials of inflammatory bowel disease 2018
- Pre-operative vedolizumab treatment and postoperative complications in patients with inflammatory bowel disease: A systematic review and meta-analysis 2018
- Systematic review and meta-analysis: Patient-reported outcomes and endoscopic appearance in ulcerative colitis 2018
- P191 Systematic review and meta-analysis: Patient-reported outcomes and endoscopic appearance in ulcerative colitis 2018
- C-reactive protein improvement after vedolizumab induction phase is associated with remission after 6 months of treatment in ulcerative colitis patients 2017
- Early use of therapeutic drug monitoring to individualize infliximab therapy in paediatric IBD: a multicentre prospective COHORT study 2017
- Impact of adalimumab's patient support program on clinical outcomes in inflammatory bowel diseases: results from the COMPANION study 2017
- Increasing treatment time on REMICADE (R) (infliximab) predicts subsequent long-term retention in stable infliximab inflammatory bowel disease patients in Canada 2017
- Persistent symptoms, CRP elevation and treatment changes over time in Crohn's disease patients are associated with bowel damage progression as expressed by deterioration of Lemann Index score 2017
- Proximal disease extension in limited ulcerative colitis: a systematic review and meta-analysis 2017
- Trends in narcotic and corticosteroid prescriptions in patients with inflammatory bowel disease in the United States ambulatory care setting from 2003 to 2011 2017
- Ulcerative colitis patients on vedolizumab lacking response at induction phase continue to improve over the first 6 months of treatment 2017
- Anxiety and depression may lead to poor health-related quality of life in patients with inflammatory bowel disease 2016
- Canadian patient and caregiver perspectives on subsequent entry biologics/biosimilars for inflammatory bowel disease 2016
- Impact of high-dose vitamin D3 supplementation in treatment of Crohn's disease in remission: a randomised double-blind controlled study 2016
- Living with inflammatory bowel disease: results from focus group 2016
- Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study 2016
- Clinical value of routine therapeutic anti-TNF drug monitoring (TDM) in Inflammatory Bowel Disease (IBD) patients in clinical practice 2015
- Correlation between the Ulcerative Colitis Endoscopic Index of severity (UCEIS) and intestinal mucosal calprotectin (IMC) in acute severe ulcerative colitis. 2015
- Systematic Review and Meta-Analysis: Infliximab or Ciclosporin as Rescue Therapy in Patients with Severe Ulcerative Colitis Refractory to Steroids 2015
- DOP040 Anti-TNF-α therapies are safe during pregnancy in patients with inflammatory bowel disease: a meta-analysis 2014
- P309 Transition experience from inpatient to ambulatory IBD care: Results of a pilot study 2014
- Use of MM-SES-CD Endoscopic Improvement Thresholds Enhances Effect Size Differentiation between Adalimumab vs. Placebo: A Post-hoc Analysis of the EXTEND Trial.. jjae171. 2024
- Outcomes of patients with prior biologic intolerance are better than those with biologic failure in clinical trials of inflammatory bowel disease.. jjae151. 2024
- Pharmacological Therapies for the Management of Fistulizing Crohn’s Disease: A Systematic Review and Meta-Analysis. 18:589-603. 2024
- Outcomes Following Acute Severe Colitis at Initial Presentation: A Multi-centre, Prospective, Paediatric Cohort Study. 18:233-245. 2024
- Efficacy and Safety of Advanced Oral Small Molecules for Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. 17:1800-1816. 2023
- Combined Histological and Endoscopic Endpoints at Post-induction Lack Additional Prognostic Value Compared with Endoscopic Improvement Alone in Ulcerative Colitis: A Post hoc Analysis of the VARSITY study. 17:1114-1121. 2023
- Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions. 17:1066-1078. 2023
- Placebo Response Rates in Randomized Controlled Trials for Perianal Crohn’s Disease: A Systematic Review and Meta-Analysis. 17:644-658. 2023
- Beyond the White Pill: Advocating for Racial Diversity in IBD Trials. 17:459-461. 2023
- Most Placebo-Controlled Trials in Inflammatory Bowel Disease were Underpowered Because of Overestimated Drug Efficacy Rates: Results from a Systematic Review of Induction Studies. 17:404-417. 2023
- Time to Endorse A Sensitive Method for Scoring Endoscopic Activity of Ulcerative Colitis in Clinical Research. 17:302-304. 2023
- Placebo Rates in Randomized Controlled Trials of Proctitis Therapy: A Systematic Review and Meta-Analysis Placebo Response in Proctitis. 17:123-136. 2023
- Categorising Endoscopic Severity of Crohn’s Disease Using the Modified Multiplier SES-CD [MM-SES-CD]. 16:1011-1019. 2022
- Efficacy and Outcomes of Faecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Children with Inflammatory Bowel Disease. 16:768-777. 2022
- Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for 1-year Endoscopic Remission in Moderate to Severe Crohn’s Disease. 16:616-624. 2022
- The Phenotypic Spectrum of New-onset IBD in Canadian Children of South Asian Ethnicity: A Prospective Multi-Centre Comparative Study. 16:216-223. 2022
- Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn’s Disease: A Post-hoc Analysis. 15:1649-1657. 2021
- Prevalence and Progression of Incidental Terminal Ileitis on Non-diagnostic Colonoscopy: A Systematic Review and Meta-analysis. 15:1455-1463. 2021
- End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn’s Disease. 15:1114-1119. 2021
- Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn’s Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials. 15:462-470. 2021
- ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment. 14:155-168. 2020
- P375 Feasibility of the first paediatric randomised controlled pilot trial of faecal microbiota transplant for ulcerative colitis. 14:S353-S354. 2020
- P416 Results of the first paediatric randomised controlled trial of faecal microbiota transplant for ulcerative colitis. 14:S379-S380. 2020
- P517 A randomised, placebo-controlled pilot trial of faecal microbiota transplantation for paediatric Crohn’s disease. 14:S447-S448. 2020
- P534 Qualitative perspectives of parent and child participants from a trial of faecal microbiota transplant for paediatric ulcerative colitis. 14:S456-S457. 2020
- P841 Evaluation of gut microbiota composition in NAFLD with UC pancolitis in clinical remission: a pilot study. 14:S650-S651. 2020
- ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. 14:4-22. 2020
- Systematic Review and Meta-Analysis: Preoperative Vedolizumab Treatment and Postoperative Complications in Patients with Inflammatory Bowel Disease. 12:538-545. 2018
- Beyond Histological Remission: Intramucosal Calprotectin as a Potential Predictor of Outcomes in Ulcerative Colitis. 11:jjw174-jjw174. 2017
- Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial. 10:925-933. 2016
- European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. 9:945-965. 2015
- Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis. 8:571-581. 2014
- Bell's palsy in a patient receiving adalimumab for Crohn's disease. 7:e115-e115. 2013
- Resource utilization during pediatric to adult transfer of care in IBD. 7:e55-e60. 2013
- Management of inflammatory bowel disease with vitamin D: Beyond bone health. 6:397-404. 2012
- Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease. 6:77-85. 2012